Serum Prostate Specific Antigen (PSA), considered as an important marker predicting prostate malignancy, has been clinically applied for prostate cancer screening and risk evaluation as well as follow-up marker after definite therapy for prostate cancer. Here, KLK3 is linked to urogenital neoplasm.